Citadel Advisors’s Renalytix plc American Depositary Shares RNLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-13,700
Closed -$2.88K 15765
2024
Q3
$2.88K Buy
+13,700
New +$4.38K ﹤0.01% 13712
2024
Q1
Sell
-15,500
Closed -$6.04K 15647
2023
Q4
$6.04K Buy
15,500
+13,200
+574% +$10.5K ﹤0.01% 13382
2023
Q3
$3.68K Sell
2,300
-6,300
-73% -$17.4K ﹤0.01% 13562
2023
Q2
$25.1K Buy
8,600
+3,400
+65% +$7.7K ﹤0.01% 12538
2023
Q1
$12.6K Sell
5,200
-900
-15% -$2.5K ﹤0.01% 13398
2022
Q4
$11.4K Buy
+6,100
New +$9.53K ﹤0.01% 13574
2022
Q2
Sell
-16,500
Closed -$114K 14384
2022
Q1
$114K Sell
16,500
-20,700
-56% -$219K ﹤0.01% 12149
2021
Q4
$591K Buy
37,200
+16,200
+77% +$324K ﹤0.01% 9275
2021
Q3
$421K Buy
21,000
+10,000
+91% +$258K ﹤0.01% 10291
2021
Q2
$339K Buy
11,000
+2,200
+25% +$65.9K ﹤0.01% 10976
2021
Q1
$226K Buy
+8,800
New +$221K ﹤0.01% 11470

Other funds holding RNLX

Citadel Advisors's RNLX Position: Q1 2024 in Review

Citadel Advisors sold out of Renalytix plc American Depositary Shares (RNLX) in Q1 2024, closing a stake of 104,392 shares — an estimated $40.7K sold.

Citadel Advisors first reported a position in RNLX in Q4 2020 and held it in 9 quarters. The position peaked at $1.89M in Q4 2021. 26 funds tracked by Wall St. Rank hold RNLX as of Q1 2024.

  • Citadel Advisors reported no remaining Renalytix plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 104,392 Renalytix plc American Depositary Shares shares in Q1 2024, an estimated $40.7K.
  • Citadel Advisors first reported a position in Renalytix plc American Depositary Shares in Q4 2020 and held it in 9 quarters.
  • Citadel Advisors's Renalytix plc American Depositary Shares position peaked at $1.89M in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Renalytix plc American Depositary Shares as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.